Kennedy Capital Management’s Aprea Therapeutics APRE Stock Holding History

Kennedy Capital Management’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-16,740	Closed	-$623K	–	602
2022 Q1	$623K	Sell	16,740 -97	-0.6%	-$3.98K	0.01%	541
2021 Q4	$966K	Sell	16,837 -287	-2%	-$25.4K	0.02%	520
2021 Q3	$1.75M	Sell	17,124 -572	-3%	-$52K	0.04%	480
2021 Q2	$1.73M	Buy	17,696 +15,075	+575%	+$1.39M	0.04%	490
2021 Q1	$267K	Buy	+2,621	New	+$306K	0.01%	639
2020 Q4	–	Sell	-9,368	Closed	-$4.51M	–	664
2020 Q3	$4.51M	Buy	9,368 +2,797	+43%	+$1.57M	0.13%	301
2020 Q2	$5.1M	Buy	6,571 +209	+3%	+$137K	0.15%	268
2020 Q1	$4.42M	Buy	6,362 +1,713	+37%	+$1.26M	0.16%	222
2019 Q4	$4.27M	Buy	+4,649	New	+$2.56M	0.1%	379

Other funds holding APRE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

Kennedy Capital Management's APRE Position: Q2 2022 in Review

Kennedy Capital Management sold out of Aprea Therapeutics (APRE) in Q2 2022, closing a stake of 16,740 shares — an estimated $623K sold.

Kennedy Capital Management first reported a position in APRE in Q4 2019 and held it in 9 quarters. The position peaked at $5.1M in Q2 2020. 33 funds tracked by Wall St. Rank hold APRE as of Q2 2022.

Kennedy Capital Management reported no remaining Aprea Therapeutics position as of Q2 2022 after selling out during the quarter.
Kennedy Capital Management sold 16,740 Aprea Therapeutics shares in Q2 2022, an estimated $623K.
Kennedy Capital Management first reported a position in Aprea Therapeutics in Q4 2019 and held it in 9 quarters.
Kennedy Capital Management's Aprea Therapeutics position peaked at $5.1M in Q2 2020.
33 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2022.

Based on Kennedy Capital Management's 13F filing for Q2 2022, filed 10 Aug 2022.